Pink Sheet“Pipeline in a pill”-style drug development will be on display in April, when more than half of the user fee goal dates are for new indications on sometimes sprawling labels, as well as one novel biol
Pink SheetElevar Therapeutics, a US subsidiary of South Korea’s HLB LifeScience, and China’s Jiangsu Hengrui Pharmaceuticals on 21 March received a complete response letter from the US Food and Drug Administrat
ScripOne key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up
Scrip“In the following 10 to 20 years, the next R&D peak in small molecules lies in protein degradation; protein degraders will have a market worth at least $100bn,” Liqiang Fu, co-founder and chief te